The_management_of_transitional_cell_carcinoma_in_solitary_renal_units._Ten_patients_with_urothelial_malignancies_involving_a_solitary_functioning_renal_unit_were_treated_at_our_center_for_an_average_of_24_months_or_until_death._These_patients_were_all_managed_by_parenchyma-sparing_methods,_including_percutaneous_as_well_as_ureteroscopic_tumor_resection._Of_our_patients_9_have_received_adjunctive_chemotherapy_in_the_form_of_bacillus_Calmette-Guerin_instillations._At_the_time_of_this_report_5_of_our_patients_were_alive_without_evidence_of_disease,_4_were_alive_with_evidence_of_either_residual_or_recurrent_neoplasia_and_1_was_dead_of_disease_5_years_after_original_presentation._Patients_with_higher_grade_tumors_or_carcinoma_in_situ_did_less_well_than_patients_with_low_grade_disease._We_present_an_analysis_of_our_experience_with_this_complex_patient_population_and_discuss_the_implications_of_these_data_within_the_context_of_a_growing_literature_on_the_topic_of_upper_tract_urothelial_malignancy.